Zoetis Bets $160M on Genomic Future with Neogen Deal

PARSIPPANY, NJ – March 02, 2026 – In a significant move to dominate the future of animal care, Zoetis Inc. announced today it has entered a definitive agreement to acquire Neogen Corporation’s animal genomics business for $160 million. The acquisition signals a major escalation in the race to harness genetic data, positioning the world's leading animal health company to accelerate its innovation in Precision Animal Health and solidify its influence over both farm and family pets.

The all-cash deal, expected to close in the second half of 2026 pending regulatory approvals, will integrate Neogen’s extensive global genomics operations into Zoetis’s already formidable portfolio. This strategic purchase is not just about acquiring assets; it's a clear statement of intent to lead the data-driven transformation of animal health, productivity, and sustainability worldwide.

A Strategic Play for the DNA Pipeline

At its core, the $160 million transaction is a calculated investment in the "DNA pipeline." Zoetis is acquiring a business that generated approximately $90 million in sales in fiscal 2025, implying a revenue multiple of roughly 1.8x. While analysts note this may be initially dilutive to Zoetis’s high-profit margins—Neogen’s genomics unit operates at mid-teens EBITDA margins compared to Zoetis's company average of around 43%—the long-term strategic value is seen as paramount.

The acquisition brings Neogen's globally recognized genomics arm, including its five state-of-the-art laboratories in the United States, Brazil, Australia, China, and the United Kingdom, under the Zoetis umbrella. This network serves customers across more than 120 countries and is a recognized leader in U.S. beef and dairy genomics, providing a ready-made infrastructure for Zoetis to expand its global reach.

For Neogen, the divestiture marks the culmination of a strategic portfolio review. The company plans to use the proceeds primarily for debt reduction, a move aimed at improving its financial health and allowing it to sharpen its focus on its core, higher-growth markets in food and animal safety. This sale allows Neogen to streamline its operations while passing a significant, albeit less profitable, business segment to a company poised to leverage its scale.

"The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data, and technology," said Jamie Brannan, Chief Commercial Officer at Zoetis, in the company's official statement. "This acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers."

The Genomic Revolution in Farming

The immediate and most profound impact of this deal will be felt in the livestock sector. Neogen’s flagship genomic tools, such as the Igenity® and GGP® lines, are industry standards for genetic prediction and herd improvement. By integrating these with Zoetis’s own established genomic testing products, like CLARIFIDE® for dairy cattle, the combined entity will offer an unparalleled suite of tools for livestock producers.

This synergy promises to empower farmers with deeper, more actionable insights than ever before. For example, a dairy farmer using Zoetis's Dairy Wellness Profit Index (DWP$), which estimates an animal's lifetime profitability, will now benefit from an even richer dataset powered by Neogen's advanced genotyping platforms. This allows for more precise decision-making in breeding for traits like disease resistance, milk production, fertility, and overall wellness. The result is a more efficient, sustainable, and profitable farm operation.

The move also advances the concept of DNA-backed traceability. With a comprehensive genetic profile for each animal, producers can better manage herd health, optimize feed and treatment protocols, and provide consumers with greater transparency about the food supply chain. By combining Neogen’s data integration platforms like Encompass™ with its own digital solutions, Zoetis is effectively building a comprehensive ecosystem for modern animal agriculture, from genetic potential to final product.

Reshaping the Competitive Landscape

This acquisition does not occur in a vacuum. It further concentrates an already consolidated animal genetics market where the top four players—Genus Plc, Hendrix Genetics, EW Group, and Zoetis—already control approximately 50% of the global share. By absorbing Neogen’s leading position in North American cattle genomics, Zoetis significantly strengthens its competitive moat against rivals like Thermo Fisher Scientific and URUS Group.

However, this consolidation is likely to attract significant regulatory scrutiny. The deal's closure is contingent on approval from bodies like the U.S. Federal Trade Commission (FTC), which has a history of intervening in animal health mergers to preserve competition. Past deals, such as Elanco's acquisition of Bayer Animal Health, have required divestitures to gain approval. Regulators will closely examine whether Zoetis's enhanced control over the genomics market could lead to reduced choice or higher prices for farmers.

Beyond market share, questions around data ownership and access will likely surface during the review process. As one company gains control over a larger portion of the "DNA pipeline," from testing to data analysis, concerns about data protection and the potential for increased switching costs for customers become more pronounced. The two-and-a-half-year timeline to closing reflects the complexities of navigating these international regulatory hurdles.

Beyond the Barn: Genomics for Companion Animals

While the primary focus of the acquisition is on livestock, the long-term implications for companion animal health are equally compelling. The advanced genomic technologies and vast data-processing capabilities that Zoetis is acquiring can be readily applied to the pet health sector, heralding a new era of personalized veterinary medicine.

Historically, Neogen’s genomics business had seen weaker performance in the companion animal segment. However, under Zoetis—a dominant force in pet pharmaceuticals, vaccines, and diagnostics—these genomic tools could be revitalized and integrated into a comprehensive wellness platform for pets. Expanded genetic testing could help veterinarians and pet owners predict the risk of hereditary diseases, understand an animal’s specific nutritional needs, and tailor preventative care plans long before symptoms appear.

For millions of pet owners, this could mean earlier detection of potential health issues, more effective treatments, and ultimately, longer, healthier lives for their animal companions. By leveraging its vast distribution network and relationships with veterinary clinics worldwide, Zoetis is uniquely positioned to bring the benefits of advanced genomics out of the research lab and into the everyday care of pets globally. The full realization of this potential will depend on how effectively the company integrates its new assets and applies these powerful technologies across all species.